Sign inJoin waitlistJoin the waitlist

Dale Bixby

Clinical Professor of Internal Medicine · University of Michigan

Credentials: · · · ·

History

University of Michigan
Present

Hematology
2006–2007
Internal Medicine
University of Michigan
2003–2006
University of Michigan Medical School
1999–2003

Research

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid…
Journal of Clinical Oncology · 2018 · 802 citations
Ponatinib in refractory Philadelphia chromosome-positive leukemias
New England Journal of Medicine · 2012 · 609 citations
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 359 citations

PB
Patrick Burke
29 papers
KP
Kristen Pettit
22 papers
MT
Moshe Talpaz
12 papers
JL
Jeffrey Lancet
9 papers
Harry Erba
8 papers
Amir Fathi
7 papers
Jessica Altman
7 papers
CF
Charles Foucar
6 papers · 2 as a fellow
James Foran
6 papers
Jorge Cortes
6 papers
Kathleen Collins
6 papers
MW
Matthew Wieduwilt
6 papers

Clinical trials

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
Principal investigator · Terminated · Phase 2
University of Michigan Rogel Cancer Center
2024–2025
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
Principal investigator · Withdrawn · Phase 1, Phase 2
University of Michigan Rogel Cancer Center
2013–2017
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha
Principal investigator · Terminated
University of Michigan Rogel Cancer Center
2009–2011
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Principal investigator · Terminated · Phase 2
University of Michigan Rogel Cancer Center
2007–2015